Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;27(10):497-502.
doi: 10.1007/s11916-023-01151-0. Epub 2023 Aug 16.

Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations

Ellen E Ingram  1 , Brooke E Bocklud  2 , Sarah C Corley  1 , Mallory A Granier  1 , Elisa E Neuchat  2 , Shahab Ahmadzadeh  3 , Sahar Shekoohi  4 , Alan D Kaye  5
Affiliations
Review

Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations

Ellen E Ingram et al. Curr Pain Headache Rep. 2023 Oct.

Abstract

Purpose of review: Although the association between CGRP and migraine disease is well-known and studied, therapies can target other pathways to minimize migraine symptoms. It is important to understand the role of these medications as options for migraine treatment and the varied mechanisms by which symptoms can be addressed. In the present investigation, the role of non-CGRP antagonist/non-triptan options for migraine disease therapy is reviewed, including NSAIDs, ß-blockers, calcium channel blockers, antidepressants, and antiepileptics. Pharmacologic therapies for both acute symptoms and prophylaxis are evaluated, and their adverse effects are compared.

Recent findings: At present, the Food and Drug Association has approved the beta-blockers propranolol and timolol and the anti-epileptic drugs topiramate and divalproex sodium for migraine prevention. Clinicians have other options for evidence-based treatment of episodic migraine attacks. Treatment decisions should consider contraindications, the effectiveness of alternatives, and potential side effects. NSAIDs are effective for the acute treatment of migraine exacerbations with caution for adverse effects such as gastrointestinal upset and renal symptoms. Beta-blockers are effective for migraine attack prophylaxis but are associated with dizziness and fatigue and are contraindicated in patients with certain co-morbidities, including asthma, congestive heart failure, and abnormal cardiac rhythms. Calcium channel blockers do not show enough evidence to be recommended as migraine attack prophylactic therapy. The anti-epileptic drugs topiramate and divalproex sodium and antidepressants venlafaxine and amitriptyline are effective for migraine exacerbation prophylaxis but have associated side effects. The decision for pharmacologic management should ultimately be made following consideration of risk vs. benefit and discussion between patient and physician.

Keywords: Antidepressants; Antiepileptics; Calcium channel blockers; Migraine disease; Non-steroidal anti-inflammatory drugs; ß-blockers.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance
    1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache. 2001;41(7):646–57. https://doi.org/10.1046/j.1526-4610.2001.041007646.x . - DOI - PubMed
    1. • Zhang N, Robbins MS. Migraine. Ann Intern Med. 2023;176(1):ITC1–16. https://doi.org/10.7326/AITC202301170 . Have described migraine diagnostic criteria, differential diagnoses, and treatment plans for migraine headache. They have delineated acute and preventative therapies and have provided examples of commonly used drug classes.
    1. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia Int J Headache. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202 . - DOI
    1. Snow V, Weiss K, Wall EM, Mottur-Pilson C, American Academy of Family Physicians, and American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002;137(10):840–9. https://doi.org/10.7326/0003-4819-137-10-200211190-00014 . - DOI - PubMed
    1. Humphrey PPA, Wasyl F. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci. 1991;12:444–6. https://doi.org/10.1016/0165-6147(91)90630-B . - DOI - PubMed

MeSH terms

LinkOut - more resources